Contrast Agents for Detecting Liver Metastases

"Affirmative. Information available on clinicaltrials.gov states that this experiment is actively seeking participants, with 55 individuals needing to be recruited from a single medical centre. The trial was first posted June 22nd 2021 and has most recently been updated October 18th 2022."

"The initial treatment method for ailments such as magnetic resonance angiography, veno-occlusive disease, and chronic liver diseases (cld) should be a Gadobenate Dimeglumine exam."

"The safety of Gadobenate Dimeglumine exam first has been rated as a 3 by Power, reflecting its Phase 4 status which confirms it is approved for medical use."

"Bracco Diagnostics, Inc., the trial sponsor, has identified quantitative measures of hepatobiliary phase images as their primary outcome. This result will be observed over a one-month duration. Secondary outcomes include comparison in sensitivity and specificity when pathology is unavailable; testing the validity of imaging methods; and comparisons on patient time associated with the imaging method."

"Affirmative. Information posted on clinicaltrials.gov states that recruitment for this medical trial is still in progress, beginning June 22nd 2021 and most recently updated October 18th 2022. 55 patients are sought to be enrolled at a single site of study."

"Currently, 5 clinical trials related to Gadobenate Dimeglumine exam first are operational with 0 studies in the final phase. 36 medical sites across the country have been designated as trial locations, with most of them situated in Aurora, Colorado."